607373-90-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinamine,N-ethyl-2-methoxy-5-nitro-(9CI) is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a building block in the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Chemical Industry:
In the chemical industry, 4-Pyridinamine,N-ethyl-2-methoxy-5-nitro-(9CI) can be utilized as a specialty chemical for the production of various chemical products. Its distinct functional groups enable it to participate in a range of chemical reactions, contributing to the creation of novel materials or improving existing ones.

Upstream product

• 31872-62-5 4-methoxy-3-nitro-pyridine 
• 607373-82-0 2-hydroxy-4-methoxy-5-nitro pyridine 

Downstream Products

• 1025507-77-0 (R)-4-cyano-N-(1-(1-ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)ethyl)benzenesulfonamide 
• 925213-65-6 [1-ethyl-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]acetonitrile 

Relevant academic research and scientific papers

Discovery of aminofurazan-azabenzimidazoles as inhibitors of rho-kinase with high kinase selectivity and antihypertensive activity

The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension. Despite many available treatments, hypertension remains a prevalent problem. In fact, some 30% of hypertensive patients are unable to reach their blood pressure goals. Thus, a new anti-hypertensive treatment, which acts on a broader patient population, would be an important addition to existing treatments. A number of vasoconstrictive agents, including angiotensin II, endothelin-1, and urotensin-II, exert their effect through RhoA and the downstream kinase Rho-kinase (ROCK1).1 Because of its central role in the control of smooth muscle contraction, inhibition of ROCK1 could lead to a more broadly efficacious anti-hypertensive agent.2 ROCK1 inhibitors have been shown to relax vascular smooth muscle and lower blood pressure in several animal models of hypertension.3 Therefore, we began an effort to identify potent ROCK1 inhibitors with pharmacokinetic profiles consistent with once daily oral dosing.